Scholars@Duke publication: The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Publication , Journal Article

Fecci, PE; Mitchell, DA; Archer, GE; Morse, MA; Lyerly, HK; Bigner, DD; Sampson, JH

Published in: J Neurooncol

2003

Despite advancements in therapeutic regimens, the prognosis remains poor for patients with malignant gliomas. Specificity has been an elusive goal for current modalities, but immunotherapy has emerged as a potential means of designing more tumor-specific treatments. Dendritic cells (DC) are the specialized antigen presenting cells of the immune system and have served now as a platform for therapeutic immunizations against such cancers as lymphoma, multiple myeloma, melanoma, prostate cancer, renal cell carcinoma, non-small cell lung carcinoma, colon cancer, and even malignant gliomas. DC-based immunizations offer a number of advantages over traditional immunotherapeutic approaches to brain tumors, approaches that have proved promising despite concerns over central nervous system immune privilege and glioma-mediated immunosuppression. The future success of clinical trials will depend on the optimization and standardizing of procedures for DC generation, loading, and administration.

Duke Scholars

Author Peter Edward Fecci Neurosurgery

Author Michael Aaron Morse Medicine, Medical Oncology

Author Darell Doty Bigner Neurosurgery

Author John Howard Sampson Neurosurgery

Published In

J Neurooncol

DOI

10.1007/BF02700031

ISSN

0167-594X

Publication Date

2003

Volume

Issue

1-2

Start / End Page

161 / 176

Location

United States

Related Subject Headings

Oncology & Carcinogenesis
Immunotherapy
Humans
History, 21st Century
History, 20th Century
Dendritic Cells
Cancer Vaccines
Brain Neoplasms
Animals
3211 Oncology and carcinogenesis

Citation

APA

Chicago

ICMJE

MLA

NLM

Fecci, P. E., Mitchell, D. A., Archer, G. E., Morse, M. A., Lyerly, H. K., Bigner, D. D., & Sampson, J. H. (2003). The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol, 64(1–2), 161–176. https://doi.org/10.1007/BF02700031

Fecci, Peter E., Duane A. Mitchell, Gary E. Archer, Michael A. Morse, H Kim Lyerly, Darell D. Bigner, and John H. Sampson. “The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.” J Neurooncol 64, no. 1–2 (2003): 161–76. https://doi.org/10.1007/BF02700031.

Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol. 2003;64(1–2):161–76.

Fecci, Peter E., et al. “The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.” J Neurooncol, vol. 64, no. 1–2, 2003, pp. 161–76. Pubmed, doi:10.1007/BF02700031.

Fecci PE, Mitchell DA, Archer GE, Morse MA, Lyerly HK, Bigner DD, Sampson JH. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol. 2003;64(1–2):161–176.